Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

Core Viewpoint - Mural Oncology plc has finalized the cash consideration for its shareholders at $2.035 per share as part of the acquisition by XOMA Royalty Corporation, with the additional price per share determined to be $0.000 [1][2]. Group 1: Acquisition Details - The acquisition involves XOMA Royalty's wholly-owned subsidiary, XRA 5 Corp., acquiring the entire issued and to be issued share capital of Mural under an Irish High Court sanctioned scheme of arrangement [2]. - The acquisition is expected to close in early December 2025, pending the satisfaction of closing conditions and the sanction of the scheme by the Irish High Court [3]. Group 2: Financial Implications - The total cash consideration payable to Mural shareholders upon closing of the acquisition will be $2.035 per share [1].